evaluation of Alendronate pharmacokinetics parameters in hemodialysis patients

evaluation of Alendronate pharmacokinetics parameters in hemodialysis patients - Alpha-HD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024439

Enrollment

Registered

2016-10-24

Start date

2016-10-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis 1) patients whose age is not less than 20 years old 2) general condition is good 3) Patients who have maintained dialysis therapy for over 6 months 4) Patients who have already diagnosed osteoporosis and treated with alendronate 5) the investigator judge the patients to be appropriate to participate in the study non-hemodialysis 1) patients whose age is not less than 20 years old 2) Patients who have already diagnosed osteoporosis and treated with alendronate 3) Creatinine clearance: more than 45 ml/min. 4) the investigator judge the patients to be appropriate to participate in the study

Exclusion criteria

Exclusion criteria: 1) Patients with severe liver disease 2) Patients with severe heart disease 3) Patients may be pregnant 4) Patients who have bad oral consitions 5) Patients who are thought to be inappropriate for this study by physician.

Design outcomes

Primary

Measure	Time frame
the plasm concentration of alendronate	—

Countries

Japan

Contacts

Public ContactKen Iseri

Makita general hospital Internal medicine

iseriken@med.showa-u.ac.jp03-3762-4671

Outcome results